Nonetheless, it has been shown that KRAS mutations, in addition to EGFR, BRAF and PIK3CA mutations, can act as predictive markers of the response to targeted therapy via the use of EGFR-TKIs in patients with NSCLC [181]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.